Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcium Fluoride→

Calcium Fluoride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7789-75-5
Molecular formula
CaF2
Molecular weight
78.07 g/mol
Drug class
Inorganic fluoride saltanticaries mineral source
Mechanism of action
Provides fluoride ions that promote remineralisation of dental enamel, enhance resistance to acid dissolution and reduce enamel demineralisation. Therapeutic effects depend on the specific dental formulation and fluoride availability.
Indications / reported uses
  • Use as a fluoride source in selected dental materials and topical anticaries preparations; calcium fluoride is not interchangeable with all sodium-fluoride varnishes or gels and should be described only within its authorised formulation

Sources: NLM MeSH — Calcium fluoride · PubMed — Calcium fluoride dental remineralisation · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Calcium Fluoride Environmental Risk Assessment (ERA) (the Calcium Fluoride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.